Zealand Pharma A/S
ACYLATED GLUCAGON ANALOGUE
Last updated:
Abstract:
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Status:
Application
Type:
Utility
Filling date:
13 May 2019
Issue date:
19 Mar 2020